In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Assoc. Prof. Pedro Barata from Case Western Reserve University, Ohio (US). They discuss the results of the ctDNA analysis in participants with renal cell carcinoma (RCC) treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial and the potential impact of these results for clinical practice. Read the abstract of this trial to know more. For more updates on kidney cancer, please visit our educational pl...